LakeShore Biopharma director files initial Form 3

LakeShore Biopharma Co., Ltd. filed an initial Form 3 to report the beneficial ownership status of director Zhao Jutao.

Accepted by SEC EDGAR 03/31/2026 - 06:37 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

LakeShore Biopharma Co., Ltd. filed an initial Form 3 to report the beneficial ownership status of director Zhao Jutao. The filing lists Zhao as a board member and indicates no reported transactions or holdings in either common stock or derivative securities at this time.

Key Terms

Form 3, reporting person, ten percent owner

3 terms

Form 3 regulatory

"filed an initial Form 3 to report the beneficial ownership status"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

reporting person regulatory

"reports director Zhao Jutao as a reporting person with no listed transactions"

ten percent owner financial

"The ten percent owner indicator is set to zero"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does LakeShore Biopharma (LSB) disclose in Zhao Jutao’s Form 3?

The Form 3 for LakeShore Biopharma reports director Zhao Jutao as a reporting person with no listed transactions or holdings. It serves as an initial statement of beneficial ownership when Zhao becomes subject to insider reporting requirements.

Does Zhao Jutao report any share transactions in LakeShore Biopharma (LSB)?

No transactions are reported for Zhao Jutao in this Form 3. The transaction summary shows zero buy, sell, acquire, dispose, or derivative transactions, indicating the filing is purely an initial ownership status statement without trading activity.

Is Zhao Jutao classified as a ten percent owner of LakeShore Biopharma (LSB)?

In this Form 3, Zhao Jutao is identified as a director but not as a ten percent owner. The ten percent owner indicator is set to zero, meaning Zhao is not reported as holding at least ten percent of the company’s equity securities.

What role does Zhao Jutao hold at LakeShore Biopharma (LSB)?

Zhao Jutao is reported as a director of LakeShore Biopharma Co., Ltd. in this Form 3. The officer status is marked as not an officer, with no officer title provided, confirming the relationship is board-level rather than an executive management position.

Does the LakeShore Biopharma (LSB) Form 3 include derivative securities for Zhao Jutao?

The Form 3 lists no derivative securities for Zhao Jutao. The derivative summary is empty and derivative transaction counts are zero, indicating there are no options, warrants, or similar derivative positions reported for the director in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Zhao Jutao

(Last) (First) (Middle)

C/O BUILDING NO. 2, 38 YONGDA ROAD

DAXING DISTRICT

(Street)

BEIJING 100020

(City) (State) (Zip)

CHINA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
LakeShore Biopharma Co., Ltd. [ LSB ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Jutao Zhao	03/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)